Trovagene presented positive early-stage trial results at a recent symposium on PCM-075, an experimental prostate cancer drug for use with Johnson & Johnson's Zytiga, or abiraterone acetate.
Trovagene reports positive results for PCM-075 in early testing
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.